• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Medtronic bankrolls drug-device trial for Nile Therapeutics heart failure treatment

March 1, 2011 By drugdelivery

Medtronic

Medtronic Inc. (NYSE:MDT) will fund a clinical trial for Nile Therapeutics Inc. (NSDQ:NLTX) behind a peptide treatment for heart failure.

The San Mateo, Calif. biopharmaceutical company said Medtronic will also provide expertise on building a drug-device combination as Nile completes a Phase I trial to “assess the pharmacokinetics and phamacodynamics of cenderitide delivered through Medtronic diabetes pump technology,” according to a prepared release .

After the study Nile will conduct a double-blind, placebo-controlled dose ranging study in patients admitted to the hospital for acute heart failure. That Phase II study will look at several endpoints, including renal function, cardiac remodeling and mortality after 90-days of continuous subcutaneous pump therapy.

Other terms of the deal were not announced, but Medtronic has made a practice of placing side bets on emerging technologies. Last January, it pumped $15 million into Lexington, Mass.-based GI Dynamics and its gastric sleeve for weight loss and has about $300 million spread around in emerging technologies, according to CEO Bill Hawkins.

Hawkins told MassDevice last fall that Fridley, Minn.-based Medtronic is always looking for new technologies it may have a strategic interest in.

“We survey the landscape continuously to see who’s doing what, whether it’s in obesity or sleep apnea, hypertension — areas that fit into this product/disease mantra,” he told us. “We’re very creative in terms of how we structure these deals in some cases its straight equity, convertible notes, in some cases debt financing. There’s no cookie cutter method for how we do a deal with a company.”

Filed Under: Drug-Device Combinations Tagged With: Nile Therapeutics

IN CASE YOU MISSED IT

  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement
  • Insulet earnings trounce Q3 estimates as it narrows guidance

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS